Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28scores

Fabiola Atzeni, Sara Bongiovanni, Antonio Marchesoni, Matteo Filippini, Roberto Caporali, Roberto Gorla, Lorenzo Cavagna, Ennio Giulio Favalli, Francesco Saccardo, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticlepeer-review


Objectives: To identify the clinical factors predicting a good clinical response to anti-TNF therapy in rheumatoid arthritis (RA) patients entered in the LORHEN registry after 5. years of treatment with anti-TNF agents and divided into two groups on the basis of their baseline DAS28scores (moderate. >. 3.2-5.1 [MDA] and high. >. 5.1 [HDA]). Methods: Disease activity at baseline and after 12. months was assessed using the DAS28, and response was evaluated using the EULAR improvement criteria. Results: The study involved 1300patients with established RA: 975 with HDA and 325with MDA. After a mean 36-month, 29.6% of the patients had a DAS28 score of less or equal to 2.6 (HDA 25.8% vs. MDA 43.0%; P

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalJoint Bone Spine
Issue number1
Publication statusPublished - Jan 2014


  • Anti-TNF
  • DAS28 scores
  • High and moderate disease activity
  • Predictive factors

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28scores'. Together they form a unique fingerprint.

Cite this